|
Final FDA Guidance on Trial Monitoring to Give More Detail on Creating Plans
An upcoming final FDA guidance on risk-based monitoring of clinical investigations will include more specifics for drugmakers on developing monitoring plans, as the industry has requested.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives